Cosmos Health Business Summary

Cosmos Health Inc. (COSM) operates as a vertically integrated global healthcare group, generating revenue through a diversified model that spans pharmaceutical wholesale, contract manufacturing, and the sale of proprietary nutraceutical brands. The company’s primary revenue driver is its Wholesale segment, anchored by Cosmofarm in Greece and Decahedron in the UK, which distributes branded and generic medicines to extensive pharmacy networks. Its manufacturing arm, Cana Laboratories, provides end-to-end production for pharmaceuticals and medical devices under European GMP standards, while its high-margin Nutraceuticals segment markets proprietary lines such as Sky Premium Life and Mediterranation. Additionally, Cosmos Health has aggressively expanded into technology-enabled services, including the ZipDoctor telehealth platform and Cloudscreen AI-driven drug repurposing. In the competitive landscape, Cosmos Health contends with players like AdaptHealth Corp., Natural Health Trends Corp., and Cardinal Health, positioning itself as a specialized, small-cap integrator that leverages European distribution infrastructure to fuel its recent entry into the U.S. market and a unique $300 million digital asset treasury strategy involving Bitcoin and Ethereum. Founded in 2009 by Grigorios Siokas in Thessaloniki, Greece, the company is led by a seasoned executive team with deep roots in European healthcare logistics. Grigorios (Greg) Siokas serves as Chairman and CEO, acting as the primary strategist and largest individual shareholder with a stake exceeding 23% following recent debt-to-equity conversions. The leadership team includes Georgios Terzis as Chief Financial Officer, who manages the firm’s complex capital structure and digital asset allocations, and Nikolaos Bardakis as Chief Operating Officer, overseeing global supply chain efficiencies. The company’s R&D efforts are directed by Dr. Dimitrios Trafalis, Head of Oncology, who leads the development of the CCX0722 obesity treatment and other clinical pipelines. Notable institutional backing includes positions from BlackRock, Vanguard, and Citadel Advisors, while the Board of Directors features experienced independent members such as Demetrios Demetriades and Anastasios Aslidis. As of early 2026, the team remains focused on a high-growth trajectory supported by recent analyst coverage from Zacks Small-Cap Research.